LIPOCINE INC (LPCN)
US53630X2036 - Common Stock
LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024
LPCN stock results show that Lipocine beat analyst estimates for earnings per share the first quarter of 2024.
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced results from a Phase 2 clinical trial (NCT04134091) which includes...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
LPCN stock results show that Lipocine beat analyst estimates for earnings per share the fourth quarter of 2023.
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lipocine (NASDAQ:LPCN) just reported results for the fourth quarter of 2023.Lip...
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced...
Lipocine to Present at 36th Annual Roth Conference
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr....
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!
Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN)
Lipocine enters license agreement with Verity Pharma for Tlando oral testosterone replacement therapy, expanding market reach to US and Canada.
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and...
Lipocine to Present at Biotech Showcase 2024
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it...
Lipocine files for $150M mixed shelf (NASDAQ:LPCN)
Lipocine (NASDAQ:LPCN) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M.This prospectus is not an offer to sell these...
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it...
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr....
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial...
Why Is National Vision (EYE) Stock Down 12% Today?
National Vision (EYE) stock is dropping on Thursday as a deal it has with Walmart (WMT) is going to come to an end in 2024.
Why Is Yellow (YELL) Stock Down 27% Today?
Yellow (YELL) stock is falling on Thursday as reports claim the transportation company is preparing to file for bankruptcy.
Why Is Lipocine (LPCN) Stock Up 32% Today?
Lipocine (LPCN) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off the day right with an overview of all the biggest pre-market stock movers traders need to know about on Thursday!
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...
Lipocine stock dips after study data of LPCN 1154 for postpartum depression
Lipocine (LPCN) stock fell ~6% on Tuesday after reporting data from a pilot pharmacokinetic bridge study of LPCN 1154 (oral brexanolone). Read more here
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone)...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...